Ignite Creation Date:
2024-05-06 @ 9:43 AM
Last Modification Date:
2024-10-26 @ 12:18 PM
Study NCT ID:
NCT03052608
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-26
First Post:
2017-01-20
Brief Title:
A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
Sponsor:
Pfizer
Organization:
Pfizer
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Carcinoma Non-Small-Cell Lung |
Keywords:
| Name | View |
|---|---|
| ALK anaplastic lymphoma kinase Non-Small-Cell Lung cancer NSCLC | View |